drug company shenanigans, this time with generics

The Boston  Globe had a front page article on a relatively new face of drug companies' relentless, seemingly inexorable pursuit of profit, this time extending more into generics. A recent blog mentioned a few generics with unconscionable price increases, noting that Daraprim (pyrimethamine) had a dramatic increase in cost (though this was apparently decreased after public outrage), as well as doxycylcine going from $20/bottle in 2013 to $1849 eighteen months later (see http://gmodestmedblogs.blogspot.com/2015/09/and-drug-company-shenanigans-continue.html ). The new Boston Globe article comments on several generic drugs increasing by up to 75 times their price over the past 2 years (see http://www.bostonglobe.com/business/2015/11/06/generic-drug-price-increases-alarm-insurers-providers-and-consumers/H3iA9CSxAUylnCdGjLNKVN/story.html?s_campaign=email_BG_TodaysHeadline&s_campaign=​  ). I will include below the examples they gave, since they did not come out in the link provided.  details:

--Globe examples (comparing 2013 to 2015 prices):
    --amitryptyline 100 mg, was $0.04/pill in 2013, now $1.03 (a 2,475% increase)
    --captopril 12.5 mg was $0.11/pill, now $0.91 (a 727% increase)
    --digoxin 0.25 mcg was  $0.12, now $0.98 (a 717% increase)
    --tetracycline 250 mg was $0.06, now $4.60/pill (a 7,567% increase)
    --clobetasol, a very potent topical steroid, increased fro $0.27/gram to $4.15/gram (a 1496% increase), meaning that a 30 gram tube went from around $8 to $125!!!

--generics comprise 80% of all prescriptions, so i guess it is not so surprising that the drug companies are targeting these drugs. and even though they are not nearly the price of the new hepatitic C drugs, many people are on these meds and often for a long time.
--a survey by the National Community Pharmacists Association found "that virtually all were grappling with 'large upswings' in the costs of generics, with 'overnight' price changes sometimes exceeding 1,000 percent"
--the issue is that drug prices are not regulated in the US (as opposed to many other countries), so there are no constraints on drug company price setting. and, there is no way that we guys in primary care have the time or ability to track these daily huge changes in pricing. And the issue is made worse by increasing mergers (eg the recent one of the generic-maker Teva Pharmaceuticals buying the generics division of Allergan PLC of Ireland in a $40.5B deal), decreasing the potential for competition
--in case you thought that overall the drug companies are fair and responsible, and that they incur great R&D costs to develop new and really important drugs, see pharmaceutical R&D bmj 2012 in dropbox, or doi: 10.1136/bmj.e4348​, which highlights how few really significant innovative drugs are actually developed (only a small minority, on the order of 10-15% are not simply look-alike drugs, such as yet another ACE inhibitor), that 80% of basic research costs actually come from public sources, and that the drug companies have a remarkably inflated assessment of the costs of drug development (which, of course, they highlight whenever questioned about the high cost of drugs). And, of course, with regard to generics, there is $0 in R&D...

so, what's wrong with this picture???

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more